Abstract Number: 2348 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
Background/Purpose: In PMR careful tailoring of the glucocorticoid dosage to the patients needs is crucial to avoid the risk of treatment-related adverse effects and the…Abstract Number: 2349 • 2012 ACR/ARHP Annual Meeting
Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica
Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR). Methods: The study included 46 patients with…Abstract Number: 2350 • 2012 ACR/ARHP Annual Meeting
Similarities Exceeds Differences in the Pattern of Joint and Vascular Positron Emission/Computed Tomography Uptake in Polymyalgia Rheumatica and Giant Cell Arteritis
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two frequent overlapping diseases. The purpose of this work is to examine the relationship between…Abstract Number: 2351 • 2012 ACR/ARHP Annual Meeting
Correlation Between Hypoechoic Halo of the Temporal Arteries and Clinical, Laboratory, and Temporal Artery Biopsy Findings in Patients with Giant Cell Arteritis
Background/Purpose: The presence of a hypoechoic halo of the temporal arteries on Color-Doppler sonography (CDS) has high specificity and acceptable sensitivity for the diagnosis of…Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting
Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…Abstract Number: 2353 • 2012 ACR/ARHP Annual Meeting
TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis of this disease is characterised by disregulated angiogenesis and inflammatory…Abstract Number: 2354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment?
Background/Purpose: Giant cell arteritis (GCA) is a common form of vasculitis mainly affecting individuals older than 50 years with a mean onset age of 69…Abstract Number: 2355 • 2012 ACR/ARHP Annual Meeting
Increase in Duration and Cumulative Dose of Glucocorticoid Therapy in Recent Decades: Observations From a Population-Based Cohort of Patients with Giant Cell Arteritis
Background/Purpose: Systemic glucocorticoid (GC) therapy is the first line treatment for giant cell arteritis (GCA). Patients with GCA are often counseled that therapy will be…Abstract Number: 2356 • 2012 ACR/ARHP Annual Meeting
Visual Manifestations in Giant Cell Arteritis : Trend Over Five Decades
Background/Purpose: Cranial ischemic complications, particularly permanent visual loss, are catastrophic complications of giant cell arteritis (GCA). Corticosteroids have been used to decrease the risk of…Abstract Number: 2357 • 2012 ACR/ARHP Annual Meeting
Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 106 Patients
Background/Purpose: In spite of the satisfactory initial response to glucocorticoid treatment, patients with giant cell arteritis (GCA) frequently experience relapses during follow-up. The objectives of…Abstract Number: 2358 • 2012 ACR/ARHP Annual Meeting
Large Vessel Giant Cell Arteritis: A Cohort Study
Background/Purpose: A subset of patients with giant cell arteritis (GCA) has large vessel (LV) involvement. We sought to identify baseline variables that distinguish patients with…Abstract Number: 2359 • 2012 ACR/ARHP Annual Meeting
Outcome of Aortic Involvement in GIANT CELL Arteritis (GCA) After 1-Year Follow-up: Prospective Study in 35 Patients Using Computed Tompography Angiography (CTA)
Background/Purpose: 65% of patients with newly diagnosed, biopsy-proven GCA showed radiologic finding of aortitis using CTA in a prospective study of 40 patients. By segments,…Abstract Number: 2360 • 2012 ACR/ARHP Annual Meeting
Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients
Background/Purpose: Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook…Abstract Number: 2361 • 2012 ACR/ARHP Annual Meeting
Misdiagnosis of Giant Cell Arteritis Presenting As Fever of Unknown Origin
Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that usually involves large and medium sized arteries. The wide spectrum…Abstract Number: 2362 • 2012 ACR/ARHP Annual Meeting
Evaluation of Disease Activity Using FDG PET-CT in Patients with Large Vessel Vasculitis
Background/Purpose: 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computerized tomography (CT) [PET/CT] has been proposed as a useful tool to diagnose and monitor activity of large vessel…
ACR Meeting Abstracts